For the quarter ending 2026-03-31, BIOA made $2,772K in revenue. -$22,458K in net income. Net profit margin of -810.17%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 2,772 | 3,078 | 2,054 | 2,412 |
| Research and development | 20,410 | 24,500 | 18,513 | 19,844 |
| General and administrative | 7,737 | 7,001 | 6,681 | 7,339 |
| Total operating expenses | 28,147 | 31,501 | 25,194 | 27,183 |
| Loss from operations | -25,375 | -28,423 | -23,140 | -24,771 |
| Interest expense | 39 | 92 | 149 | 201 |
| Interest and other income (expense), net | 3,268 | 2,792 | 3,160 | 3,420 |
| Loss on extinguishment of debt | - | 0 | 0 | 0 |
| Gain (loss) from changes in fair value of warrants | -107 | -220 | -42 | -11 |
| Total other income (expense), net | 3,122 | 2,480 | 2,969 | 3,208 |
| Net loss | -22,253 | -25,943 | -20,171 | -21,563 |
| Unrealized holding gains (losses) on available-for-sale investments | -178 | 20 | 73 | 0 |
| Foreign currency translation adjustment | -27 | -17 | -10 | -52 |
| Total other comprehensive income(loss) | -205 | 3 | 63 | -52 |
| Total comprehensive loss | -22,458 | -25,940 | -20,108 | -21,615 |
| Basic EPS | -0.52 | -0.717 | -0.56 | -0.6 |
| Diluted EPS | -0.52 | -0.717 | -0.56 | -0.6 |
| Basic Average Shares | 42,480,488 | 36,181,545 | 35,850,037 | 35,850,037 |
| Diluted Average Shares | 42,480,488 | 36,181,545 | 35,850,037 | 35,850,037 |
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)